CN118028156A - Brevibacillus laterosporus with blood glucose and lipid reducing effects and application thereof - Google Patents
Brevibacillus laterosporus with blood glucose and lipid reducing effects and application thereof Download PDFInfo
- Publication number
- CN118028156A CN118028156A CN202410136739.9A CN202410136739A CN118028156A CN 118028156 A CN118028156 A CN 118028156A CN 202410136739 A CN202410136739 A CN 202410136739A CN 118028156 A CN118028156 A CN 118028156A
- Authority
- CN
- China
- Prior art keywords
- asd0001
- group
- mice
- brevibacillus laterosporus
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000193417 Brevibacillus laterosporus Species 0.000 title claims abstract description 28
- 239000008280 blood Substances 0.000 title claims abstract description 25
- 210000004369 blood Anatomy 0.000 title claims abstract description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 22
- 230000001603 reducing effect Effects 0.000 title claims abstract description 22
- 239000008103 glucose Substances 0.000 title claims abstract description 21
- 150000002632 lipids Chemical class 0.000 title claims abstract description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 230000000055 hyoplipidemic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000004321 preservation Methods 0.000 abstract description 3
- 210000000577 adipose tissue Anatomy 0.000 abstract description 2
- 239000002689 soil Substances 0.000 abstract description 2
- 230000009772 tissue formation Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 52
- 235000009200 high fat diet Nutrition 0.000 description 17
- 230000037396 body weight Effects 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 4
- 230000011759 adipose tissue development Effects 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000013116 obese mouse model Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a Brevibacillus laterosporus strain with the effects of reducing blood sugar and lipid and application thereof. The strain is Brevibacillus laterosporus (Brevibacillus laterosporus) ASD0001, and the preservation number is GDMCC No:63890. The Brevibacillus laterosporus is autonomously screened from soil, has the effects of reducing the weight of obese animals, inhibiting adipose tissue formation and improving glucose tolerance and insulin resistance of the obese animals, can be applied to preparing products with functions of reducing blood sugar and lipid or products for preventing and treating diabetes, and has good market application prospects.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to Brevibacillus laterosporus with the effects of reducing blood sugar and lipid and application thereof.
Background
With the improvement of the living standard of people, the proportion of obese people is higher and higher, and obesity has become one of the most serious public health problems in the global scope. The world obesity Association has recently issued a global obesity map of 2023 showing that by 2035, over 40 million people worldwide will be obese or overweight, accounting for 51% of the general population. The obesity causes various reasons, besides the well-known problems of diet structure, emotion, exercise frequency, living habit and the like, and the obesity problem is difficult to be regulated by singly depending on diet and is difficult to be sustained. However, obesity is not only related to the problem of visual appearance, but also important for human health, for example, obesity is often accompanied with diseases of heart and cerebral vessels, liver, kidney and other parts, so how to control the occurrence of obesity is more and more important for human health.
In addition to diet, exercise, regular life, etc., weight loss by medication is a relatively easy way to control obesity. Several drugs are commonly known, one being digestive enzyme inhibitors such as orlistat, which, by binding to pancreatic lipase in the intestine, prevent the breakdown and absorption of glycerol and fat in the food; the other is an appetite suppressant, such as dexfenfluramine, fenfluramine, and the like, which is a drug that suppresses appetite by stimulating neurotransmitter production, release and inhibiting its reuptake, essentially by reducing food intake. However, taking these chemically synthesized weight-reducing drugs may cause serious side effects, such as dry mouth, constipation, dizziness, insomnia, etc., and the national food and drug administration has stopped the production, sales and use of sibutramine preparations and raw materials in China since 2010. As another example, orlistat can cause adverse gastrointestinal reactions including flatulence, stool urgency, increased stool frequency, and lipidic stool. The semaglutin has high attention in the weight-losing market, can realize two effects of reducing blood sugar and weight, and has the main mechanism that the semaglutin can promote insulin secretion in a glucose concentration dependent manner by activating GLP-1 (glucagon-like peptide-1) receptor, inhibit glucagon secretion, delay gastric emptying to increase satiety and inhibit appetite by inhibiting the action of hypothalamic feeding center, so that the effect of reducing blood sugar and weight is achieved, but the semaglutin also has certain side effects.
Therefore, developing a weight-reducing product with little side effect and good effect is a category of current market shortage.
Disclosure of Invention
The first object of the invention is to provide a Brevibacillus laterosporus (Brevibacillus laterosporus) ASD0001 strain with the effects of reducing blood sugar and lipid. The strain was deposited at the cantonese microbiological strain collection center (GDMCC), address: 30, building 5, post code of 30 # 100 college in Guangzhou city View area martyr: 510070, the preservation number is GDMCCNo:63890, and the preservation date is 2023, 10, 19.
The second purpose of the invention is to provide the application of the Brevibacillus laterosporus ASD0001 in preparing products with the functions of reducing blood sugar and lipid.
Preferably, the active ingredient of the functional product for reducing blood glucose and lipid comprises thallus of Brevibacillus laterosporus ASD0001 or a fermentation product thereof.
Preferably, the functional product for reducing blood sugar and lipid comprises food, health care products or medicines.
The third object of the invention is to provide the application of the Brevibacillus laterosporus ASD0001 in preparing products for preventing and treating diabetes.
Preferably, the product for preventing and treating diabetes comprises health care products or medicines.
The fourth object of the present invention is to provide a functional product for lowering blood sugar and reducing blood lipid, which comprises as an active ingredient a bacterial cell of Brevibacillus laterosporus ASD0001 or a fermentation product thereof.
A fifth object of the present invention is to provide a product for preventing and treating diabetes, which comprises as an active ingredient a bacterial cell of Brevibacillus laterosporus ASD0001 or a fermentation product thereof.
The invention has the following beneficial effects:
The Brevibacillus laterosporus is autonomously screened from soil, has the effects of reducing the weight of obese animals, inhibiting adipose tissue formation and improving glucose tolerance and insulin resistance of the obese animals, can be applied to preparing products with functions of reducing blood sugar and lipid or products for preventing and treating diabetes, and has good market application prospects.
Brevibacillus laterosporus (Brevibacillus laterosporus) ASD0001 was deposited at the microorganism strain collection (GDMCC) of Guangdong province, 5 th floor of the No. 100 college of Guangzhou city martyr, post code: 510070, accession number is: GDMCC No:63890.
Drawings
FIG. 1 shows the weight difference between BL1 and ASD0001 mice after 4 weeks of high fat diet feeding. A: the body shape comparison of the mice in the 6 th four groups is that: control group (C), model group (H), BL1 group (BL 1), ASD0001 group (ASD 0001); b: four groups of mice were assayed for 6 weeks of body weight. * Representing the significance of differences in body weight of ASD0001 group versus model group and BL1 group, * represents p < 0.05, ** represents p < 0.01.
FIG. 2 shows the weight difference of Inguinal White Adipose Tissue (iWAT) of BL1 and ASD0001 mice after 4 weeks of high-fat diet feeding. A: four groups of mice iWAT were photographed, in order from left to right: control group (C), model group (H), BL1 group (BL 1), ASD0001 group (ASD 0001); b: four groups of mice iWAT were assayed by weight. ## Representing that the difference between the group H and the group C is extremely significant p < 0.01, ** represents that the difference between ASD0001 and the group H and the group BL1 is extremely significant p < 0.01.
FIG. 3 shows the epididymal white adipose tissue (eWAT) weight difference between BL1 and ASD0001 mice after 4 weeks of high-fat diet feeding. A: four groups of mice were photographed with eWAT, in order from left to right: control group (C), model group (H), BL1 group (BL 1), ASD0001 group (ASD 0001); b: four groups of mice were weighed. ## Representing that the difference between the group H and the group C is extremely significant p < 0.01, ** represents that the difference between ASD0001 and the group H is extremely significant p < 0.01, and * represents that the difference between ASD0001 and the group BL1 is significantly p < 0.05.
FIG. 4 shows the results of oil red O staining of liver tissue of BL1 and ASD0001 mice after 4 weeks of high-fat diet feeding. In the figure, C: control group, H: model group, BL1: BL1 treatment group, ASD0001: ASD0001 treatment group.
FIG. 5 shows the glucose tolerance differences between BL1 and ASD0001 mice after 4 weeks of high fat diet feeding. In the figure, C: control group, H: model group, BL1: BL1 treatment group, ASD0001: ASD0001 treated group ## represents very significant p < 0.01 for group H compared to group C, ** represents very significant p < 0.01 for ASD0001 compared to group H.
FIG. 6 shows the difference in insulin resistance between BL1 and ASD0001 mice after 4 weeks of high-fat diet feeding. In the figure, C: control group, H: model group, BL1: BL1 treatment group, ASD0001: ASD0001 treated group ## represents very significant p < 0.01 in comparison to group C, * represents significant p < 0.05 in comparison to group H.
Detailed Description
The invention is further illustrated in the following drawings and specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
The following examples relate to strain Brevibacillus laterosporus BL1, deposited under the accession number GDMCC No:62699, which is disclosed in the literature Weng GY,Huang J,et al.Brevibacillus laterosporus BL1,a promising probiotic,prevents obesity and modulates gut microbiota in mice fed a high-fat diet.Frontiers in Nutrition.2022Nov 24:9:1050025.
Example 1: lipid lowering effect of Brevibacillus laterosporus ASD0001
40 Male C57BL/6 mice (purchased from the Betty Biotechnology Co., ltd.) of 5 weeks old were individually kept in a controlled environment (24.+ -. 2 ℃ C., 45-60% relative humidity, 12h/12h light and dark cycle) and were free to eat during the whole experiment. After 1 week of adaptation, the mice were randomly divided into 4 groups (n=10 per group), respectively, control group (C), model group (H), BL1 group (BL 1), ASD0001 group (ASD 0001), wherein the mice of the control group were fed normal diet (cat No. XTCON50 0J, available from the company limited), while the mice of the model group, BL1 group, and ASD0001 group were fed high fat diet (cat No. XTHF60, available from the company limited), and after 4 weeks of high fat diet, the mice of the BL1 group and ASD0001 group were respectively perfused with the strain BL1 (1×10 9 CFU/d) and ASD0001 (1×10 9 CFU/d) for 6 weeks, and the mice of the control group and model group were perfused with an equal volume of normal saline. Body Weight (BW) of mice was recorded weekly. At the end of 6 weeks of treatment, the mice body weight was determined. After mice were sacrificed, the liver, inguinal White Adipose Tissue (iWAT) and epididymal white adipose tissue (eWAT) were taken, weights of iWAT and eWAT were measured, and the liver was fixed and then oil red O staining was performed to observe the adipogenesis level of the liver tissue, and the results are shown in FIGS. 1 to 4.
Figure 1 shows that after 4 weeks of high fat diet feeding mice (week 0 for weight calculation), the weight was significantly higher than the control group C mice. BL1 and ASD0001 were fed for 6 weeks, and model group H mice were significantly obese compared to control group C mice. BL1 and ASD0001 mice were significantly leaner than model group H (FIG. 1A). The body weight of each group of mice was measured weekly, and from the results, BL1 group and ASD0001 group were lower than model group H in each of the groups after 1-6 weeks of feeding with the bacterial liquid. After 5 and 6 weeks of feeding, ASD0001 group mice had significantly lower body weight than model group H and significantly lower body weight than BL1 group. It was demonstrated that ASD0001 was more effective in controlling body weight of obese mice than strain BL 1.
FIG. 2 shows that after 4 weeks of high fat diet feeding mice, BL1 and ASD0001 were fed for 6 weeks, each group of mice was dissected and iWAT weight was measured. From the results, iWAT weight of model group H was significantly higher than control group C, iWAT weight of the ASD0001 and BL1 bacteria fed mice was significantly lower than model group H, and iWAT weight of ASD0001 was significantly lower than BL 1. It was demonstrated that ASD0001 was more effective in reducing the formation of mice iWAT compared to strain BL 1.
FIG. 3 shows that after 4 weeks of high fat diet feeding mice, BL1 and ASD0001 were fed for 6 weeks, each group of mice was dissected and eWAT weights were determined. From the results, the weight of the eWAT was significantly higher in model group H than in control group C, the weight of the eWAT was significantly lower in ASD 0001-and BL 1-fed mice than in model group H, and the weight of the eWAT was significantly lower in ASD0001 group than in BL1 group. It was demonstrated that ASD0001 was more effective in reducing the formation of mouse eWAT compared to strain BL 1.
FIG. 4 shows that after 4 weeks of high fat diet feeding mice, BL1 and ASD0001 were infused for 6 weeks, liver tissue was dissected from each group of mice, and the adipogenesis level of liver tissue was compared in four groups of mice. As can be seen, the adipogenesis level of model group H was significantly higher than that of control group C. The ASD0001 group and BL1 bacteria group can effectively reduce the adipogenesis of mice. It was demonstrated that ASD0001 was more effective in reducing fat formation in the liver than strain BL 1.
Example 2: hypoglycemic effect of Brevibacillus laterosporus ASD0001
40 Male C57BL/6 mice of 5 weeks old were individually kept in a controlled environment (24.+ -. 2 ℃ C., 45-60% relative humidity, 12h/12h light and dark cycle) and were free to eat throughout the experiment. After 1 week of adaptation, the mice were randomly divided into 4 groups (n=10 per group), respectively, control group (C), model group (H), BL1 group (BL 1), ASD0001 group (ASD 0001), wherein the mice of the control group were fed normal diet (cat No. XTCON50 0J, available from the company limited), while the mice of the model group, BL1 group, and ASD0001 group were fed high fat diet (cat No. XTHF60, available from the company limited), and after 4 weeks of high fat diet, the mice of the BL1 group and ASD0001 group were respectively perfused with the strain BL1 (1×10 9 CFU/d) and ASD0001 (1×10 9 CFU/d) for 6 weeks, and the mice of the control group and model group were perfused with an equal volume of normal saline. Abdominal glucose tolerance test (IGTT) and insulin resistance test (ITT) were performed at week 7. Tail vein blood glucose levels were measured using a glucometer. IGTT analysis, mice were intraperitoneally injected with glucose (2 g/kg body weight) after overnight fast, and then blood glucose levels were measured at injection 0, 15, 30, 60, 90, and 120 min. ITT analysis, mice were intraperitoneally injected with insulin (0.75U/kg body weight) 6h after fasting, and then blood glucose levels at 0, 15, 30, 60, 90, and 120min were measured. The results are shown in FIGS. 5-6.
Figure 5 shows that ASD0001 and BL1 were fed 6 weeks after 4 weeks of high fat diet feeding to mice. Mice fasted overnight were intraperitoneally injected with glucose (2 g/kg body weight) and blood glucose levels were measured at 0, 15, 30, 60, 90 and 120min, respectively, with model group H glucose levels on average significantly higher than control group C. After 30, 60, 90 and 120min post glucose injection, the blood glucose levels were significantly lower in ASD0001 and BL1 groups than in model group H. For high-fat induced obese mice, ASD0001 was more effective in improving glucose tolerance in mice than strain BL1.
Figure 6 shows that ASD0001 and BL1 were fed 6 weeks after 4 weeks of high fat diet feeding to mice. After 6h of fasted mice, insulin (0.75U/kg body weight) was intraperitoneally injected and blood glucose levels were measured at 0, 15, 30, 60, 90 and 120min, respectively. Model group H was higher than control group C at each time. The blood glucose levels were lower in the asd0001 group than in the model group H and BL1 groups at 15min and 120min after insulin injection. For fat-induced obese mice, ASD0001 was more effective in improving insulin resistance in mice than strain BL1.
The foregoing is merely a preferred embodiment of the present invention, and it should be noted that the above-mentioned preferred embodiment should not be construed as limiting the invention, and the scope of the invention should be defined by the appended claims. It will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the spirit and scope of the invention, and such modifications and adaptations are intended to be comprehended within the scope of the invention.
Claims (8)
1. Brevibacillus laterosporus (Brevibacillus laterosporus) ASD0001, accession number: GDMCC No:63890.
2. The use of Brevibacillus laterosporus ASD0001 in preparing a hypoglycemic and hypolipidemic functional product.
3. The use according to claim 2, wherein the active ingredient of the functional product for reducing blood glucose and lipid comprises the thallus of Brevibacillus laterosporus ASD0001 or the fermentation product thereof.
4. The use according to claim 2, wherein the functional product for reducing blood glucose and blood lipid comprises a food, a health product or a pharmaceutical product.
5. Use of Brevibacillus laterosporus ASD0001 in the preparation of a product for preventing and treating diabetes.
6. The use according to claim 5, wherein the product for preventing and treating diabetes comprises a health product or a pharmaceutical product.
7. A functional product for reducing blood glucose and lipid comprising the Bacillus laterosporus ASD0001 or a fermentation product thereof according to claim 1 as an active ingredient.
8. A product for preventing and treating diabetes, comprising the Brevibacillus laterosporus ASD0001 or a fermentation product thereof as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410136739.9A CN118028156A (en) | 2024-01-31 | 2024-01-31 | Brevibacillus laterosporus with blood glucose and lipid reducing effects and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410136739.9A CN118028156A (en) | 2024-01-31 | 2024-01-31 | Brevibacillus laterosporus with blood glucose and lipid reducing effects and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118028156A true CN118028156A (en) | 2024-05-14 |
Family
ID=90985145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410136739.9A Pending CN118028156A (en) | 2024-01-31 | 2024-01-31 | Brevibacillus laterosporus with blood glucose and lipid reducing effects and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118028156A (en) |
-
2024
- 2024-01-31 CN CN202410136739.9A patent/CN118028156A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2702977T3 (en) | Bifidobacteria for the treatment of diabetes and related conditions | |
| Fukumoto et al. | Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats | |
| JP6316501B2 (en) | Composition for treatment or prevention of metabolic diseases comprising extracellular vesicles derived from Ackermansia mucinifira as an active ingredient | |
| CN111035014A (en) | Probiotic preparation and preparation method thereof | |
| WO2023116227A1 (en) | Microbial combination having weight loss effect and application thereof | |
| CN110892990B (en) | Probiotic and prebiotic edible composition and application thereof | |
| TW202136496A (en) | Lactobacillus fermentum strain and composition for preventing or treating metabolic disease including the same | |
| CN117065006A (en) | Combination drug containing microorganism and hypoglycemic and hypolipidemic drug | |
| JP4132635B2 (en) | Uninactivated enzyme-enhanced composition | |
| JP6793380B2 (en) | Evaluation method, screening method and manufacturing method of substances that suppress the rise in blood glucose level due to sucrose intake | |
| CN111304134B (en) | Lactobacillus plantarum capable of effectively relieving diabetes | |
| CN118028156A (en) | Brevibacillus laterosporus with blood glucose and lipid reducing effects and application thereof | |
| CN114540257B (en) | Lactobacillus crispatus IOB901 and application thereof in aspects of reducing blood sugar and blood fat | |
| CN109965290B (en) | Meal replacement powder for improving intestinal flora and application thereof | |
| US10342852B2 (en) | Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein | |
| CN104906114A (en) | Metformin-gliquidone compound sustained-release capsule and preparation method thereof | |
| CN108653298A (en) | Monosaccharide composition, pharmaceutical preparation and its application | |
| CN109045070A (en) | A kind of composition for preventing and treating non-alcoholic fatty liver disease | |
| KR20180125895A (en) | Composition with Lactobacillus sp. KCCM 11826P for preventing, treating or improving disease from uremic toxins | |
| JP2019210269A (en) | Composition for treating diabetic disease | |
| CN113384600A (en) | Application of inactivated lactobacillus compound in preparation of product for treating and/or preventing diabetes | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof | |
| CN104906115A (en) | Melbine and gliquidone compound sustained-release tablet and preparation method thereof | |
| CN111358961A (en) | Application of Tibetan medicine eighteen-ingredient myrobalan diuretic pill and test method of brain protection effect of Tibetan medicine eighteen-ingredient myrobalan diuretic pill on type 2 diabetic encephalopathy rats | |
| CN109260235A (en) | A kind of application of composition in preparation prevention and treatment constipation drug or health care product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |